| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 09/19/2002 | US20020133011 Alcoholism, psychological disorders |
| 09/19/2002 | US20020132979 Monoclonal antibody for use in the diagnosis, prevention and treatment of tumors |
| 09/19/2002 | US20020132973 Peptide parathyroid hormone analogs |
| 09/19/2002 | US20020132852 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use |
| 09/19/2002 | US20020132849 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 09/19/2002 | US20020132842 Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them |
| 09/19/2002 | US20020132833 Caspase inhibitors and uses thereof |
| 09/19/2002 | US20020132824 1,5-methylene-3-benzazepines used in treatment of neurological and psychological disorders,especially withdrawl from nicotine addiction |
| 09/19/2002 | US20020132822 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 09/19/2002 | US20020132816 Estrogen agonists/antagonists for preventing breast cancer |
| 09/19/2002 | US20020132812 Oral hypoglycaemic agents |
| 09/19/2002 | US20020132809 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production |
| 09/19/2002 | US20020132806 Treatment of atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X |
| 09/19/2002 | US20020132799 Vitamin D3 dervative and treating agent for inflammatory respiratory disease using same |
| 09/19/2002 | US20020132796 Treatment or prevention of the diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid. |
| 09/19/2002 | US20020132775 Human potassium channel 1 and 2 proteins |
| 09/19/2002 | US20020132773 Methods for reducing fat by administration of adiponectin |
| 09/19/2002 | US20020132772 Administered to delay the clinical onset of diabetes, to reduce the occurrence of beta cell destruction, to provide a regulating effect on spleen T cells, or to reduce the likelihood of the occurrence of clinical diabetes |
| 09/19/2002 | US20020132296 Human Ste20-like stress activated serine/threonine kinase |
| 09/19/2002 | US20020132279 Adjusting glucose concentration in humans; obtain carbohydrate sufficient to adjust blood glucose, ingest, monitor blood glucose concentration |
| 09/19/2002 | US20020132223 Methods for modulating activity of the FXR nuclear receptor |
| 09/19/2002 | US20020132030 Edible microbiocide of .05-1.0% alkyl paraben, and .1-.2% benzoic and sorbic acids salts |
| 09/19/2002 | US20020132018 Use of non-alkalized cocoa solids in a drink |
| 09/19/2002 | US20020132014 Administering amounts of calcium to induce a metabolic change; inducing the loss of adipose tissue; stimulating lipolysis, inhibiting lipogenesis, and increasing the expression of white adipose tissue uncoupling protein 2 (UCP2) |
| 09/19/2002 | US20020132001 Delayed-release formulation of aldosterone antagonist drug which when orally administered 6-12 hours prior to acrophase provides profile of plasma drug concentration corresponding to diurnal cycle of plasma aldosterone concentration |
| 09/19/2002 | DE10112151A1 New 5-(4-(indolyl-alkyl)-piperazino)-benzofuran-2-carboxamides useful e.g. for treating depression, anxiety, psychiatric or cerebral disorders or pain, are 5-HT-1A receptor agonists and 5-HT reuptake inhibitors |
| 09/19/2002 | DE10110754A1 Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use |
| 09/19/2002 | DE10110438A1 Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and their use |
| 09/19/2002 | DE10058461A1 Substituierte Cyclohexanderivate und ihre Verwendung Substituted cyclohexane derivatives and their use |
| 09/19/2002 | CA2702192A1 Igf antagonist peptides |
| 09/19/2002 | CA2473979A1 Method for identifying inhibitors of g protein coupled receptor signaling |
| 09/19/2002 | CA2473156A1 Rxr activating molecules |
| 09/19/2002 | CA2458451A1 Use of sugar phosphates, amino acids, amino acid analogs, e.g. carbomethoxypropionyl cyanide for reducing weight or diabetes complications |
| 09/19/2002 | CA2440773A1 Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules |
| 09/19/2002 | CA2440670A1 Agent for therapeutic and/or prophylactic treatment of diabetic ischemic heart disease |
| 09/19/2002 | CA2440647A1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same |
| 09/19/2002 | CA2440618A1 Immunoglobulin superfamily proteins |
| 09/19/2002 | CA2440282A1 Diphenyl derivatives |
| 09/19/2002 | CA2440166A1 Salvia hispanica l. (chia) in the management and treatment of cardiovascular disease, diabetes and associated risk factors |
| 09/19/2002 | CA2440144A1 Methods for reducing fat by administration of adiponectin |
| 09/19/2002 | CA2439774A1 Compositions and methods for non-insulin glucose uptake |
| 09/19/2002 | CA2439735A1 Igf antagonist peptides |
| 09/19/2002 | CA2439498A1 Somatostatin antagonists |
| 09/19/2002 | CA2439063A1 Combination of nateglinide or repaglinide with at least one further antidiabetic compound |
| 09/19/2002 | CA2438874A1 Fluorinated trienes and their use as rxr modulators |
| 09/19/2002 | CA2438586A1 Retinoid x receptor modulators |
| 09/19/2002 | CA2437963A1 Therapeutic binding molecules |
| 09/18/2002 | EP1241256A1 Novel gene and use thereof |
| 09/18/2002 | EP1241170A2 Pyrazolopyrimidine derivatives |
| 09/18/2002 | EP1241169A1 Isoindoloindolone derivatives, process for their preparation and pharmaceutical compositions containing them |
| 09/18/2002 | EP1240823A1 N-calcium channel knockout animal |
| 09/18/2002 | EP1240822A1 Diabetes onset model mammal |
| 09/18/2002 | EP1240518A1 Markers for identification and isolation of pancreatic islet alpha and beta cell progenitors |
| 09/18/2002 | EP1240313A2 Homologues of human heparanase and splice variants thereof |
| 09/18/2002 | EP1240285A1 Stabilisation of pigments and polyunsaturated oils and oil concentrates |
| 09/18/2002 | EP1240199A2 Method for screening of appetite control agents |
| 09/18/2002 | EP1240197A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1240195A2 Polynucleotides and polypeptides encoded thereby |
| 09/18/2002 | EP1240194A2 Novel human protein kinases and protein kinase-like enzymes |
| 09/18/2002 | EP1240171A1 Cyclopenteneone derivatives |
| 09/18/2002 | EP1240168A1 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 09/18/2002 | EP1240158A1 1-(aminophenyl)-2-pyrrolidones as integrin inhibitors |
| 09/18/2002 | EP1240145A2 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof |
| 09/18/2002 | EP1240143A1 New modulators of dopamine neurotransmission |
| 09/18/2002 | EP1240142A1 New modulators of dopamine neurotransmission |
| 09/18/2002 | EP1240141A1 New modulators of dopamine neurotransmission |
| 09/18/2002 | EP1240137A1 Method for making 24(s)-hydroxyvitamin d 2 |
| 09/18/2002 | EP1239885A1 Interventions to mimic the effects of calorie restriction |
| 09/18/2002 | EP1239881A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239871A1 Use of glp-1 agonists for the inhibition of beta cell degeneration |
| 09/18/2002 | EP1239870A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1239863A2 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 09/18/2002 | EP1239854A1 Use of a hypoglycemic agent for treating impaired glucose metabolism |
| 09/18/2002 | EP1239848A2 Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| 09/18/2002 | EP1239845A2 Hydroxide-releasing agents as skin permeation enhancers |
| 09/18/2002 | EP1239839A2 Hydrogel-driven layered drug dosage form comprising sertraline |
| 09/18/2002 | EP1239837A2 Direct compression polymer tablet core |
| 09/18/2002 | EP1239836A1 Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same |
| 09/18/2002 | EP1239826A2 Cosmetic and/or pharmaceutical preparations |
| 09/18/2002 | EP0994854B1 Method for preparing a substituted perhydroisoindole |
| 09/18/2002 | EP0975573B1 Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
| 09/18/2002 | EP0954565A4 Adipogenic differentiation of human mesenchymal stem cells |
| 09/18/2002 | EP0952837B1 Use of mixtures of active substances, containing phytostenols and/or phytostenol esters and potentiators, for the production of hypocholesteremic agents |
| 09/18/2002 | EP0915697B1 Anticonvulsant sulfamate derivatives useful in treating obesity |
| 09/18/2002 | EP0841923B1 1h-4(5)-substituted imidazole derivatives |
| 09/18/2002 | EP0840604B1 Non-beta-oxidizable fatty acid analogues, their uses as therapeutic active medicaments, and preparation thereof |
| 09/18/2002 | EP0823889B1 1,3-propane diol derivatives as bioactive compounds |
| 09/18/2002 | CN1370238A Human poly(ADP-ribose) polymerase 2 materials and methods |
| 09/18/2002 | CN1370181A Effectors of dipeptidyl peptidase IV for topical use |
| 09/18/2002 | CN1370180A Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease |
| 09/18/2002 | CN1370179A Aromatic and heterocyclic derivatives of phytosterols and/or phytosanols for use in treating or preventing cardiovascular disease |
| 09/18/2002 | CN1370176A Subsstituted heterocycle fused gamma-carbolines |
| 09/18/2002 | CN1370169A Substituted heterocycle fused gamma-carbolines |
| 09/18/2002 | CN1370159A Indole derivatives and their use for treatment of osteoporosis amongst other applications |
| 09/18/2002 | CN1370154A Aminothiazole derivatives and their use as CRF receptor ligands |
| 09/18/2002 | CN1370143A Propanoic acid derivatives that inhibit binding of integrins to their receptors |
| 09/18/2002 | CN1370068A Pharmaceutical agent comprising benzamide derivative as active ingredient |
| 09/18/2002 | CN1370067A Use of monoamine oxidase inhibitors for manufacture of drugs intended for treatment of obesity |
| 09/18/2002 | CN1370066A Methods and compsns. for regulating gut motility and food intake |
| 09/18/2002 | CN1369280A 'Kangneng Pingheng' oral liquid |